Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.

F1000Res 2015 29;4:30. Epub 2015 Jan 29.

Section of Virology, St Mary's Campus, Imperial College London, London, W2 1PG, UK.

Emerging viral diseases pose a threat to the global population as intervention strategies are mainly limited to basic containment due to the lack of efficacious and approved vaccines and antiviral drugs. The former was the only available intervention when the current unprecedented Ebolavirus (EBOV) outbreak in West Africa began. Prior to this, the development of EBOV vaccines and anti-viral therapies required time and resources that were not available. Therefore, focus has turned to re-purposing of existing, licenced medicines that may limit the morbidity and mortality rates of EBOV and could be used immediately. Here we test three such medicines and measure their ability to inhibit pseudotype viruses (PVs) of two EBOV species, Marburg virus (MARV) and avian influenza H5 (FLU-H5). We confirm the ability of chloroquine (CQ) to inhibit viral entry in a pH specific manner. The commonly used proton pump inhibitors, Omeprazole and Esomeprazole were also able to inhibit entry of all PVs tested but at higher drug concentrations than may be achieved in vivo. We propose CQ as a priority candidate to consider for treatment of EBOV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431382PMC
http://dx.doi.org/10.12688/f1000research.6085.2DOI Listing
June 2015

Publication Analysis

Top Keywords

emerging viral
8
viral diseases
8
ebov
5
three medicines
4
medicines measure
4
test three
4
ebov test
4
mortality rates
4
rates ebov
4
measure ability
4
ability inhibit
4
viruses pvs
4
pvs ebov
4
ebov species
4
pseudotype viruses
4
marburg virus
4
morbidity mortality
4
inhibit pseudotype
4
species marburg
4
medicines limit
4

Similar Publications